Shingles prevention vaccine study for kids with kidney transplants
Part of Infections clinical trials.
This study tests whether an investigational shingles (herpes zoster) vaccine is safe and helps prevent shingles in children who have had a kidney transplant. Because these children take medicines to prevent rejection, the study specifically looks at vaccine effects in this higher-risk group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 1 and 17 years old (and weigh at least 6 kg / 13.23 lb)
- Have a kidney transplant done more than 6 months ago (180 days), with kidney function stable per study rules
- Be on ongoing anti-rejection medicines for at least 1 month before starting the study
- Know your chickenpox (varicella) immunity status—either past chickenpox/vaccine, confirmed past infection, or a blood test showing you’ve had it
- If biologically female and able to get pregnant, use reliable birth control starting 30 days before vaccination and continue through 2 months after the vaccine series ends
- Be able to follow study visits and rules (including a 7-day diary before vaccination)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new shingles vaccine to see how well it prevents shingles in adults aged 40 and older. It aims to help those who have not had shingles recently or been vaccinated against it before.
This trial tests an experimental vaccine designed to prevent shingles (a painful rash caused by the varicella-zoster virus). It will help see if the vaccine is safe and triggers a good immune response in adults 40 and older.
This study tests an investigational vaccine (SYS6017) to see how well it works and if it's safe for adults 40 and older. The vaccine aims to prevent shingles, a painful rash caused by the same virus as chickenpox.
This trial tests a new investigational shingles vaccine to see if it is safe and produces an immune response in healthy adults 40 and older. Participating could help protect against shingles and its complications.
This trial is testing an experimental mRNA vaccine for preventing shingles. It aims to see if the vaccine is safe and triggers a good immune response in people aged 50 to 79.
This study tests a new vaccine to prevent shingles (a painful rash condition) in adults 50 and older. It checks how safe the vaccine is and how well it triggers the body's immune defense.
Hear when a new Herpes Zoster trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.